Related Experiment Videos

Identifying high-risk and actionable profiles for prevention in hypertensive patients with concurrent dyslipidemia: a

Yizhou Xu1, Hansong Huang2, Jiaqi Wang3

  • 1Department of Operations Management, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.

BMC Cardiovascular Disorders
|June 6, 2026
PubMed

Insights

Hypertension and dyslipidemia co-occur frequently in China. Key risk factors include high BMI, family history of heart disease, and conditions like stroke, suggesting targets for early intervention and prevention.

Area of Science:

  • Cardiology
  • Public Health
  • Clinical Medicine

Background:

  • Hypertension and dyslipidemia are leading global risk factors for cardiovascular diseases.
  • China faces a significant 'dual high' epidemic of hypertension and dyslipidemia.
  • Understanding factors associated with comorbid hypertension and dyslipidemia is crucial for public health initiatives.

Purpose of the Study:

  • To analyze clinical factors associated with dyslipidemia in hypertensive patients in China.
  • To identify independent predictors for the co-occurrence of hypertension and dyslipidemia.

Main Methods:

  • A multivariate logistic regression model was used.
  • Data from 5,018 hypertensive patients across 110 Chinese hospitals were analyzed.
  • Patients were grouped into dyslipidemia and non-dyslipidemia categories based on diagnostic criteria.

Main Results:

  • The dyslipidemia group showed higher prevalence of stroke, angina pectoris, atrial fibrillation, and specific medication use.
  • Significant correlates of hypertension with dyslipidemia included Body Mass Index (BMI), family history of hypertension, stroke, angina pectoris, atrial fibrillation, and coronary heart disease.
  • Obstructive sleep apnea was also identified as a correlate.

Conclusions:

  • Comorbid hypertension and dyslipidemia are significantly correlated with BMI and familial predisposition.
  • Individual medical histories and medication regimens are associated with disease progression.
  • Findings support a three-tier prevention strategy, emphasizing screening and early intervention for high-risk individuals.
Abstract

Keywords:
BMIDyslipidemiaFamily historyHypertensionThree-tier prevention system

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...